What is the available evidence supporting the rationale for comprehensive molecular profiling across a broad continuum of solid tumor subtypes?
Does FoundationOne’s comprehensive genomic profiling have validation studies confirming accuracy across multiple alterations in a peer-reviewed journal? Please discuss. Do you know of any other genomic profiling services that are clinically ...
What is the clinical rationale for incorporating genomic target-driven therapies into the front lines of oncology practice? Can we expect NGS to uncover more molecular drivers and actionable mutations over time?
What is the role of NGS-based mutational testing in patients with triple-negative breast cancer?
At what point in the natural history of a cancer, in the individual patient, do you recommend that NGS-CGP with a hybrid capture-based platform like FoundationOne be performed? And what do you do with this information at each point in time?
What specific molecular targets are detected by the NGS hybrid capture platform, how is actionability determined, and what are the translational implications of molecular drivers across the cancer spectrum?
Can you contrast and compare different platforms for genomic profiling—hot spot panels, mammoprint, CGP with hybrid capture, and others—and explain why CGP platforms, such FoundationOne, with hybrid capture have emerged as the gold standard?
Why have molecular drivers for cancer therapy been embraced by the academic oncology community in China, and what role does NGS testing and comprehensive genomic profiling—such as that provided by FoundationOne and other laboratories—currently ...
PFS is improved with use of a TKI in patients with sensitizing EGFR mutations when compared with standard chemotherapy. Please summarize clinical results and implications for NGS testing.
What kind of clinical samples are required to implement next generation sequencing (NGS)? Can NGS be applied to samples other than FFPE?
What evidence and guidelines have supported the move by oncologists toward molecular, NGS-generated mutational drivers as the optimal approach to precision cancer medicine?
In what types of solid tumors has mutation-directed therapy been shown to improve patient outcomes, including progression-free survival (PFS) and overall (OS)?